🇺🇸 FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11865288

Devices for applying a topical treatment

THERMA BRIGHT INC · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11866450

Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical composit

Vertex Pharmaceuticals Incorporated · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11865134

Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11857641

Method for the treatment of mucopolysaccharidosis type I

Sangamo Therapeutics, Inc. · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11857531

Combination mast cell inhibition for treatment of BPH/LUTS

Northwestern University · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11851653

Materials and methods for treatment of alpha-1 antitrypsin deficiency

CRISPR THERAPEUTICS AG · Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11851690

Systems and methods for the treatment of hemoglobinopathies

Editas Medicine, Inc. · Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11851481

Treatment of central nervous system disorders by intranasal administration of immunoglobul

Takeda Pharmaceutical Company Limited · Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11850229

Treatment of circadian rhythm disorders

VANDA PHARMACEUTICALS INC. · Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11844765

Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusi

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11844801

Oral compositions of MK2 pathway inhibitor for treatment of immune conditions

Aclaris Therapeutics, Inc. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11844805

Formulations of testosterone and methods of treatment therewith

The Board of Regents of the University of Texas System · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11845752

Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis B

Aligos Therapeutics, Inc. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11845989

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11840497

4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases

PTC THERAPEUTICS, INC. · Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11840525

Use of AURKB small-molecule inhibitors for treatment of non-small cell lung cancer

NANJING CHINA-AUSTRALIA INSTITUTE OF TRANSLATIONAL MEDICINE CO., LTD. · Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11839619

Methods for treatment of pediatric systemic mastocytosis

The Regents of the University of California · Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11839596

Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

United Therapeutics Corporation · Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11839604

Use of sublingual dexmedetomidine for the treatment of agitation

BioXcel Therapeutics, Inc. · Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11839631

Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progeni

United Therapeutics Corporation · Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11833211

Methods of suppression and treatment of disease comprising administering bicycle peptide l

BicycleTx Limited · Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11833130

Treatment of circadian rhythm disorders

VANDA PHARMACEUTICALS INC. · Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11833160

Ursodeoxycholic acid derivatives as HDAC inhibitors for the treatment of polycystic diseas

UNIVERSIDAD DEL PAÍS VASCO / EUSKAL HERRIKO UNIBERTSITATEA · Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11833210

ASH1L inhibitors and methods of treatment therewith

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted